Emergence of DNA damage repair clonal haematopoiesis after peptide receptor radionuclide therapy for neuroendocrine tumours

#4355

Introduction: In neuroendocrine tumours (NETs), PRRT (Peptide Receptor Radionuclide Therapy), has shown efficacy but with significant hematologic toxicity. Clonal haematopoiesis (CHIP) is considered a risk factor for therapy-related myeloid neoplasms (t-MN).

Aim(s): The association between PRRT and development of CHIP was assessed.

Materials and methods: Next Generation Sequencing (NGS) in blood samples of 153 pretreated patients (pts) with metastatic gastroenteropancreatic NET, including (n=102) or not (n=51) PRRT. Mutations in TP53, PPM1D, CHEK2 and ATM genes were considered as DNA damage repair (DDR) mutations.

Conference:

Presenting Author: Hadoux J

Authors: Loyaux R, Hadoux J, Oziel-Taieb S, Durand A, Bouhier Leporrier K,

Keywords: PRRT, clonal haematopoiesis, DNA Damage Repair, therapy-related myeloid neoplasm, Neuroendocrine tumour,